Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 7.76 SEK 0.78% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Vicore Pharma Holding AB
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vicore Pharma Holding AB
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Vicore Pharma Holding AB
STO:VICO
Revenue
kr104.2m
CAGR 3-Years
N/A
CAGR 5-Years
265%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Revenue
kr1.3B
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Revenue
kr814.5m
CAGR 3-Years
58%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Revenue
kr3.6B
CAGR 3-Years
32%
CAGR 5-Years
21%
CAGR 10-Years
22%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Revenue
kr25.4B
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
26%
BioArctic AB
STO:BIOA B
Revenue
kr616m
CAGR 3-Years
115%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Vicore Pharma Holding AB
Glance View

Market Cap
1.8B SEK
Industry
Biotechnology

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

VICO Intrinsic Value
2.86 SEK
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Vicore Pharma Holding AB's Revenue?
Revenue
104.2m SEK

Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's Revenue amounts to 104.2m SEK.

What is Vicore Pharma Holding AB's Revenue growth rate?
Revenue CAGR 5Y
265%

Back to Top